[go: up one dir, main page]

MX2017003220A - Metodos y formulaciones para reducir la absorcion de carbohidratos en un animal de compañia. - Google Patents

Metodos y formulaciones para reducir la absorcion de carbohidratos en un animal de compañia.

Info

Publication number
MX2017003220A
MX2017003220A MX2017003220A MX2017003220A MX2017003220A MX 2017003220 A MX2017003220 A MX 2017003220A MX 2017003220 A MX2017003220 A MX 2017003220A MX 2017003220 A MX2017003220 A MX 2017003220A MX 2017003220 A MX2017003220 A MX 2017003220A
Authority
MX
Mexico
Prior art keywords
companion animal
carbohydrates
reducing absorption
formulations
methods
Prior art date
Application number
MX2017003220A
Other languages
English (en)
Inventor
Pan Yuanlong
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017003220A publication Critical patent/MX2017003220A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/45—Semi-moist feed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención proporciona métodos para reducir la absorción de carbohidratos en un animal de compañía, que comprende identificar al animal de compañía que tiene una afección médica o que se encuentra en riesgo de la afección médica asociada con alta ingestión de carbohidratos y alimentar con una formulación dietética en una cantidad terapéuticamente eficaz al animal de compañía. Tales formulaciones dietéticas pueden ser cualquiera de las descritas en la presente descripción. Generalmente, la formulación dietética puede comprender 20 % a 60 % de proteína, 10 % a 40 % de grasa, 10 % a 50 % de carbohidratos y 0.01 % a 5 % de inhibidor de alfa-amilasa. Típicamente, la cantidad terapéuticamente eficaz puede ser eficaz para reducir la absorción de carbohidratos en el animal de compañía según se evalúa mediante la disminución de la glucosa postprandial en sangre del animal en comparación con la glucosa postprandial en sangre del animal de compañía que ingiere una formulación dietética comparable que excluye al inhibidor de alfa-amilasa.
MX2017003220A 2014-09-19 2015-09-17 Metodos y formulaciones para reducir la absorcion de carbohidratos en un animal de compañia. MX2017003220A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052580P 2014-09-19 2014-09-19
US201462052584P 2014-09-19 2014-09-19
PCT/IB2015/057175 WO2016042517A1 (en) 2014-09-19 2015-09-17 Methods and formulations for reducing absorption of carbohydrates in a companion animal

Publications (1)

Publication Number Publication Date
MX2017003220A true MX2017003220A (es) 2017-07-20

Family

ID=54207644

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003220A MX2017003220A (es) 2014-09-19 2015-09-17 Metodos y formulaciones para reducir la absorcion de carbohidratos en un animal de compañia.

Country Status (11)

Country Link
US (1) US20160082057A1 (es)
EP (1) EP3193899A1 (es)
JP (1) JP2017534258A (es)
CN (1) CN106686988A (es)
AU (1) AU2015319790A1 (es)
BR (1) BR112017003516A2 (es)
CA (1) CA2960362A1 (es)
CO (1) CO2017002018A2 (es)
MX (1) MX2017003220A (es)
RU (1) RU2017113155A (es)
WO (1) WO2016042517A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921229D0 (en) * 1999-09-08 1999-11-10 Med Eq As Compositions
JP2004091462A (ja) * 2002-09-02 2004-03-25 Oriza Yuka Kk 糖質吸収阻害剤
JP2006104181A (ja) * 2004-09-13 2006-04-20 Takahiro Tsujita ブナ科植物由来の糖質分解酵素阻害物質、及びその用途
US20110256261A1 (en) * 2007-08-10 2011-10-20 Univ Iowa State Res Found Resistant food starches and methods related thereto
WO2013025201A1 (en) * 2011-08-16 2013-02-21 Abbott Laboratories Method of transforming a meal

Also Published As

Publication number Publication date
US20160082057A1 (en) 2016-03-24
CO2017002018A2 (es) 2017-06-09
BR112017003516A2 (pt) 2017-12-05
AU2015319790A1 (en) 2017-02-23
WO2016042517A1 (en) 2016-03-24
RU2017113155A (ru) 2018-10-19
CA2960362A1 (en) 2016-03-24
CN106686988A (zh) 2017-05-17
EP3193899A1 (en) 2017-07-26
JP2017534258A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
PH12017502350A1 (en) Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants
BR112015023484A2 (pt) composição de carboidrato, produto e processso para preparar uma composição de carboidrato
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
WO2015034812A3 (en) A new ketogenic diet and its use in treating the critically ill
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
AR102085A1 (es) Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados
MY175322A (en) Composition comprising okra for use in reducing dietary fat absorption
AR097151A1 (es) Alimento para rumiantes lactantes
MX2017004662A (es) Composiciones y metodos para mejorar la movilidad o actividad o tratar la fragilidad.
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2017006639A (es) Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso.
MX2017003217A (es) Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía.
MY179829A (en) Anti-regurgitation nutritional composition
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
BR112016002655A2 (pt) composição, uso da composição, produto alimentício e método para preservar um produto alimentício
CO2017005383A2 (es) Composiciones inhibidoras
MY181189A (en) Nutritional compositions containing ceramide
MX2022012719A (es) Composiciones de desoxirribonucleosidos para uso en el tratamiento de enfermedades mitocondriales.
MX2017003220A (es) Metodos y formulaciones para reducir la absorcion de carbohidratos en un animal de compañia.
AR101217A1 (es) Composiciones nutricionales que contienen lactosa hidrolizada
BR112015021781A2 (pt) alta dose única de mva induz uma resposta imune protetora em neonatos e lactentes
CL2017000531A1 (es) Métodos y formulaciones para reducir la absorción de carbohidratos en un animal de compañia